NCT04293393 2026-03-12
CARABELA
Spanish Breast Cancer Research Group
Phase 2 Active not recruiting
Clinical Trials
72 trialsNCT02712723 2026-03-11
FELINE
University of Kansas Medical Center
Phase 2 Active not recruiting
NCT02778685 2026-02-24
Pembrolizumab, Endocrine Therapy, and Palbociclib in Treating Postmenopausal Patients With Newly Diagnosed Metastatic Stage IV Estrogen Receptor Positive Breast Cancer
City of Hope Medical Center
Phase 2 Active not recruiting
NCT03179904 2026-02-24
TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer
Mayo Clinic
Phase 2 Active not recruiting
NCT02520063 2026-02-06
Combination of Letrozole, Everolimus and TRC105 in Postmenopausal Women With Hormone-Receptor Positive and Her2 Negative Breast Cancer
University of Alabama at Birmingham
Phase 1/2 Completed
NCT03879577 2026-01-21
Assessing the Response Rate of Neo-adjuvant Taxotere and Trastuzumab in Nigerian Women With Breast Cancer
University of Chicago
Phase 2 Active not recruiting
NCT01068249 2025-11-18
Letrozole and RAD001 With Advanced or Recurrent Endometrial Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT02764541 2025-05-07
Palbociclib and Endocrine Therapy for LObular Breast Cancer Preoperative Study (PELOPS)
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT02040857 2025-04-29
Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive, HER2 Negative Invasive Breast Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT03219476 2025-04-29
Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Node-Negative Breast Cancer
Medical College of Wisconsin
Phase 2 Completed
NCT00265759 2025-04-23
Exemestane, Letrozole, or Anastrozole in Treating Postmenopausal Women Who Are Undergoing Surgery for Stage II or Stage III Breast Cancer
Alliance for Clinical Trials in Oncology
Phase 3 Completed
NCT05206448 2025-04-15
CLC II
University of Iowa
Phase 4 Active not recruiting
NCT03691493 2025-02-17
ASPIRE
Emory University
Phase 2 Completed
NCT03774472 2025-02-17
Hydroxychloroquine, Palbociclib, and Letrozole Before Surgery in Treating Patients With Estrogen Receptor Positive, HER2 Negative Breast Cancer
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT04294225 2025-01-28
Anastrozole and Letrozole After Surgery for the Treatment of Stage I-III Breast Cancer
Mayo Clinic
Phase 2 Completed
NCT04256941 2024-12-27
Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT Study
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT01897441 2024-12-24
Chemotherapy Before Surgery and Tissue Sample Collection in Patients With Stage IIA-IIIC Breast Cancer
Albert Einstein College of Medicine
Phase NA Terminated
NCT01870505 2024-12-09
BYL719 Plus Letrozole or Exemestane for Patients With Hormone-Receptor Positive Locally-Advanced Unresectable or Metastatic Breast Cancer
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT02491983 2024-12-09
PARSIFAL
MedSIR
Phase 2 Completed
NCT04129216 2024-05-07
The Effects of Short-term Preoperative Treatment With Hormonal Therapy on Gene Profiles in Breast Cancer
Johns Hopkins University
Phase 2 Completed
NCT01353209 2024-04-17
TRAIL
University of Cincinnati
Phase 2 Completed
NCT03007979 2024-03-20
Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer
Washington University School of Medicine
Phase 2 Completed
NCT02648477 2024-03-19
Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer
City of Hope Medical Center
Phase 2 Completed
NCT01814397 2024-02-07
Pilot Study to Evaluate the Effect of Aromatase Inhibitor Therapy on Pain Threshold in Breast Cancer Patients
University of Michigan Rogel Cancer Center
Completed
NCT03054363 2023-11-13
Tucatinib, Palbociclib and Letrozole in Metastatic Hormone Receptor Positive and HER2-positive Breast Cancer
University of Colorado, Denver
Phase 1/2 Completed
NCT00634634 2023-11-09
Phase I/II Trial of Letrozole and Sorafenib in Post-Menopausal Hormone-Receptor + Breast Cancer
Rutgers, The State University of New Jersey
Phase 1/2 Completed
NCT00579826 2023-06-12
Study of Breast Cancer Prevention by Letrozole in High Risk Women
University of Kansas Medical Center
Phase 2 Completed
NCT04177693 2023-06-05
Pharmacokinetics and Hepatic Safety of EGCG
Yale University
Phase 1 Completed
NCT00545077 2023-03-31
Bevacizumab + Endocrine Treatment vs Endocrine Treatment as First Line in Postmenopausal Women
Spanish Breast Cancer Research Group
Phase 3 Completed
NCT01642186 2022-12-29
Study of (1) Everolimus, (2) Estrogen Deprivation Therapy (EDT) With Leuprolide + Letrozole and (3) Everolimus + EDT in Patients With Unresectable Fibrolamellar Hepatocellular Carcinoma (FLL-HCC)
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT01035099 2022-12-13
RCT of Fixed vs Titrated Letrozole in Breast Cancer Patient Undergoing IVF
Weill Medical College of Cornell University
Phase 4 Completed
NCT00530868 2022-10-21
Comparing Letrozole Given Alone to Letrozole Given With Avastin in Post-Menopausal Women Breast Cancer
University of Alabama at Birmingham
Phase 2 Completed
NCT01791985 2022-08-22
RADICAL
Imperial College London
Phase 1/2 Completed
NCT03874325 2022-05-31
Aromatase Inhibitor and Durvalumab in Postmenopausal Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Terminated
NCT01999569 2022-04-22
The Role of Estrogen in Luteinizing Hormone Surge and Ovulation
Wake Forest University Health Sciences
Phase 4 Completed
NCT02269670 2022-04-05
Phase II Study of Everolimus Beyond Progression
Emory University
Phase 2 Terminated
NCT01499160 2022-02-11
Letrozole and Lapatinib Followed by Everolimus in Women With Advanced Breast Cancer
University of Maryland, Baltimore
Phase 2 Terminated
NCT02657928 2021-10-26
Ribociclib and Letrozole in Treating Patients With Relapsed ER Positive Ovarian, Fallopian Tube, Primary Peritoneal, or Endometrial Cancer
Mayo Clinic
Phase 2 Completed
NCT03633331 2021-10-15
Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer
Alliance for Clinical Trials in Oncology
Phase 2 Unknown
NCT02907918 2021-09-29
PALTAN
Washington University School of Medicine
Phase 2 Terminated
NCT02692755 2021-09-28
PALINA
Georgetown University
Phase 2/3 Completed
NCT01669343 2021-05-13
Aromatase Inhibitor Host Factors Study
Samuel Lunenfeld Research Institute, Mount Sinai Hospital
Phase NA Completed
NCT00461773 2021-03-16
Randomized Phase II Study of Preoperative Letrozole (Femara) in Combination With Avastin in Hormone Receptor Positive Breast Cancer
Yale University
Phase 2 Terminated
NCT02283658 2020-10-23
Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer
Mayo Clinic
Phase 2 Completed
NCT02291913 2020-02-17
Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer
SCRI Development Innovations, LLC
Phase 2 Completed
NCT00338728 2020-01-27
Letrozole and Imatinib Mesylate in Treating Postmenopausal Participants With Estrogen or Progesterone Positive Metastatic Breast Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01720602 2020-01-07
Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Hormone Therapy
University of Washington
Phase NA Completed
NCT02470741 2019-11-15
PLUM
University of California, San Francisco
Phase 4 Completed
NCT00436917 2019-09-11
Zoledronate in Treating Osteopenia or Osteoporosis in Postmenopausal Women Receiving Letrozole for Stage I, Stage II, or Stage IIIA Primary Breast Cancer
Mayo Clinic
Phase NA Completed
NCT01153672 2019-09-06
Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Aromatase Inhibitor Therapy
University of Washington
Phase NA Completed